AMGN
NASDAQ · Biotechnology
Amgen Inc
$351.85
+2.85 (+0.82%)
Financial Highlights (FY 2026)
Revenue
37.02B
Net Income
7.77B
Gross Margin
82.5%
Profit Margin
21.0%
Rev Growth
+11.8%
D/E Ratio
6.31
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.5% | 82.5% | 50.3% | 50.3% |
| Operating Margin | 24.7% | 22.2% | 1.8% | 2.2% |
| Profit Margin | 21.0% | 19.9% | 1.5% | 1.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 37.02B | 33.12B | 561.58B | 538.84B |
| Gross Profit | 30.55B | 27.33B | 282.31B | 270.88B |
| Operating Income | 9.15B | 7.37B | 10.30B | 11.85B |
| Net Income | 7.77B | 6.25B | 8.50B | 9.25B |
| Gross Margin | 82.5% | 82.5% | 50.3% | 50.3% |
| Operating Margin | 24.7% | 22.2% | 1.8% | 2.2% |
| Profit Margin | 21.0% | 19.9% | 1.5% | 1.7% |
| Rev Growth | +11.8% | +11.8% | +24.6% | +7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 82.17B | 82.17B | 59.25B | 55.06B |
| Total Equity | 13.03B | 13.03B | 120.16B | 131.87B |
| D/E Ratio | 6.31 | 6.31 | 0.49 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 9.78B | 8.31B | 18.36B | 16.26B |
| Free Cash Flow | — | — | 5.30B | 5.02B |